MedTrace Logo

GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers

NCT06076070 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-10-10

No results posted yet for this study

Summary

Multicenter noninterventional, translational study, retrospective/prospective designed in order to assess the aptitude to the use of genomic profiling methods for therapeutic purposes and evaluation by the institutional Molecular Tumor Board (MTB) of sarcoma patients with metastatic/locally advanced disease that is inoperable with no viable therapeutic alternatives or with histotypes known to be resistant to available in-label medical treatments and without already therapeutically validated driver mutations.

Conditions

  • Sarcoma

Sponsors & Collaborators

  • Candiolo Cancer Institute - IRCCS

    collaborator OTHER

  • Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

    collaborator NETWORK

  • Istituto Oncologico Veneto IRCCS

    collaborator OTHER

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    collaborator OTHER

  • Istituto Ortopedico Rizzoli

    collaborator OTHER

  • Ospedale Pediatrico Bambin Gesù

    collaborator OTHER

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    collaborator OTHER

  • Istituti Tumori Giovanni Paolo II

    collaborator NETWORK

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    collaborator OTHER

  • Regina Elena Cancer Institute

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2024-05-25
Completion
2024-05-25

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06076070 on ClinicalTrials.gov